DNA methylation subtypes guiding prognostic assessment and linking to responses the DNA methyltransferase inhibitor SGI-110 in urothelial carcinoma

• Published in: BMC medicine Vol. 20; no. 1; pp. 1 - 17
• Main Authors: Li, Juan, Liang, Yuan, Fan, Jian, Xu, Chunru, Guan, Bao, Zhang, Jianye, Guo, Bin, Shi, Yue, Wang, Ping, Tan, Yezhen, Zhang, Qi, Yuan, Changwei, Wu, Yucai, Zhou, Liqun, Ci, Weimin, Li, Xuesong
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 18.07.2022; BioMed Central; BMC
• Subjects: Adenocarcinoma; Bisulfite; Bladder cancer; Cancer; Cell adhesion & migration; Deoxyribonucleic acid; DNA; DNA methylation; DNA methylation subtype; DNA methyltransferase; DNA methyltransferase inhibitor; Epigenetics; Gene expression; Gene sequencing; Genetic aspects; Genomes; Haplotypes; Health aspects; Inhibitors; Invasiveness; Lymphocytes; Lymphocytes T; Medical prognosis; Methods; Methylation; Methyltransferases; Muscles; Patients; Prognosis; Software; Tumors; Upper tract urothelial carcinoma; Urothelial carcinoma; Urothelial carcinoma of the bladder; Whole-genome bisulfite sequencing; China; United States > US
• ISSN: 1741-7015; 1741-7015
• DOI: 10.1186/s12916-022-02426-w

Background At present, the extent and clinical relevance of epigenetic differences between upper tract urothelial carcinoma (UTUC) and urothelial carcinoma of the bladder (UCB) remain largely unknown. Here, we conducted a study to describe the global DNA methylation landscape of UTUC and UCB and to address the prognostic value of DNA methylation subtype and responses to the DNA methyltransferase inhibitor SGI-110 in urothelial carcinoma (UC). Methods Using whole-genome bisulfite sequencing (n = 49 samples), we analyzed epigenomic features and profiles of UTUC (n = 36) and UCB (n = 9). Next, we characterized potential links between DNA methylation, gene expression (n = 9 samples), and clinical outcomes. Then, we integrated an independent UTUC cohort (Fujii et al., n = 86) and UCB cohort (TCGA, n = 411) to validate the prognostic significance. Furthermore, we performed an integrative analysis of genome-wide DNA methylation and gene expression in two UC cell lines following transient DNA methyltransferase inhibitor SGI-110 treatment to identify potential epigenetic driver events that contribute to drug efficacy. Results We showed that UTUC and UCB have very similar DNA methylation profiles. Unsupervised DNA methylation classification identified two epi-clusters, Methy-High and Methy-Low, associated with distinct muscle-invasive statuses and patient outcomes. Methy-High samples were hypermethylated, immune-infiltrated, and enriched for exhausted T cells, with poor clinical outcome. SGI-110 inhibited the migration and invasion of Methy-High UC cell lines (UMUC-3 and T24) by upregulating multiple antitumor immune pathways. Conclusions DNA methylation subtypes pave the way for predicting patient prognosis in UC. Our results provide mechanistic rationale for evaluating SGI-110 in treating UC patients in the clinic. Keywords: Upper tract urothelial carcinoma, Urothelial carcinoma of the bladder, Whole-genome bisulfite sequencing, DNA methylation subtype, Prognosis, DNA methyltransferase inhibitor